Mar. 23 at 8:34 PM
$BCDA I asked Google AI about the likelihood of BCDA's Helix Transendocardial Delivery Catheter receiving FDA approval, and it said this: "It appears high, driven by its status as a foundational "breakthrough" technology with extensive supporting data. On 03-17-2026, the FDA accepted the pre-submission package for the device, and a substantive review and meeting are scheduled for early Q2 2026.
Key indicators supporting potential approval include:
Breakthrough Designation: The Helix catheter supports the CardiAMP Cell Therapy System, which has already been granted FDA Breakthrough Designation, highlighting its potential to meet unmet medical needs.
Substantial Evidence: The submission is based on safety and performance data from twelve to fifteen well-controlled cell and gene therapy clinical studies.
Strong Clinical Performance: The Helix has been used in over 4,000 intramyocardial deliveries, showing superior therapeutic agent retention and safety compared to other delivery methods.
